Research In Brief
This article was originally published in The Gray Sheet
NEJM's impact on vertebroplasty: Vertebroplasty and vertebral augmentation procedures have declined 10% since studies published in the August New England Journal of Medicine found the procedures had no lasting benefit, according to a Millennium Research Group report. The report, based on a survey of 245 U.S. physicians, said the decrease in procedures was largely due to fewer patient referrals. MRG notes that 70% of specialists who perform vertebroplasty compression fracture (VCF) treatments disagree with the NEJM findings, versus 30% of referring physicians. In the blinded, randomized, placebo-controlled studies, the treatment showed no significant difference in the primary endpoint of overall pain up to six months post-procedure (1"The Gray Sheet" Aug. 10, 2009)
You may also be interested in...
The first two blinded, randomized, placebo-controlled trials of vertebroplasty treatment for spinal fractures suggest that the procedure may have no lasting benefit, researchers report in the Aug. 6 New England Journal of Medicine
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.